These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 25817916)

  • 1. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
    Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
    Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Min KS; Park K; Park JK
    Eur Urol; 2011 Aug; 60(2):380-7. PubMed ID: 21458153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
    Munk NE; Knudsen JS; Comerma-Steffensen S; Simonsen U
    Sex Med Rev; 2019 Jul; 7(3):430-441. PubMed ID: 30711478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDE5 inhibitors: considerations for preference and long-term adherence.
    Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
    Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.
    Porst H; Gacci M; Büttner H; Henneges C; Boess F
    Eur Urol; 2014 Feb; 65(2):455-64. PubMed ID: 24119319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
    Liao X; Qiu S; Bao Y; Wang W; Yang L; Wei Q
    World J Urol; 2019 Jun; 37(6):1061-1074. PubMed ID: 30523399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
    Yafi FA; Sharlip ID; Becher EF
    Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of phosphodiesterase-5 inhibitors for treating erectile dysfunction in kidney transplant recipients: a meta-analysis.
    Fanbin L; Mei Y; Yan Z; Yirong Y; Shaoling Z; Yong C; Peng X
    Exp Clin Transplant; 2014 Jun; 12(3):184-9. PubMed ID: 24907716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.
    Madeira CR; Tonin FS; Fachi MM; Borba HH; Ferreira VL; Leonart LP; Bonetti AF; Moritz RP; Trindade ACLB; Gonçalves AG; Fernandez-Llimos F; Pontarolo R
    World J Urol; 2021 Mar; 39(3):953-962. PubMed ID: 32388784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
    Hsu JC; Tang DH; Lu CY
    Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Tadalafil Once-a-Day versus Tadalafil On-Demand in Patients with Erectile Dysfunction: A Systematic Review and Meta-Analyses.
    Peng Z; Yang L; Dong Q; Wei Q; Liu L; Yang B
    Urol Int; 2017; 99(3):343-352. PubMed ID: 28628914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.
    Lombardo R; Tema G; De Nunzio C
    Curr Drug Targets; 2021; 22(1):31-37. PubMed ID: 32981502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.
    Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Moon KH; Chung WS; Min KS; Suh JK; Hyun JS; Park K; Park JK
    BJU Int; 2012 Dec; 110(11):1801-6. PubMed ID: 22448738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study.
    Ortaç M; Çayan S; Çalişkan MK; Yaman MÖ; Okutucu TM; Semerci MB; Altay AB; Balbay MD; Özcan MF; Kadioğlu A
    Andrology; 2013 Jul; 1(4):549-55. PubMed ID: 23785019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
    Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
    Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial.
    Park HJ; Park JK; Park K; Min K; Park NC
    J Sex Med; 2010 Jun; 7(6):2209-2216. PubMed ID: 20412426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Berner MM; Kriston L; Harms A
    Int J Impot Res; 2006; 18(3):229-35. PubMed ID: 16239897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.